Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Noriyo Urata is active.

Publication


Featured researches published by Noriyo Urata.


Liver cancer | 2014

Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy

Miwa Kawanaka; Ken Nishino; Jun Nakamura; Takahito Oka; Noriyo Urata; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Masatoshi Kudo; Gotaro Yamada

Background: Serum levels of hepatitis B virus (HBV) DNA are an important predictor of the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV infection. However, little is known about whether high levels of hepatitis B surface antigen (HBsAg) increase the risk for HCC. Methods: We investigated 167 patients who were treated with nucleos(t)ide analogues (NA) for at least 2 years (median: 5.8 years, range: 2-13.1 years). Relationships between reduced levels of HBsAg and various factors were evaluated. In addition, we evaluated the usefulness of quantitative serum levels of HBV DNA and HBsAg as predictors of HCC development in patients receiving long-term NA therapy. Results: HCC developed in 9 of the 167 NA-treated patients. In the 9 patients with HCC, HBV DNA was undetectable (<2.1 log copies/mL), but HBsAg levels were ≥2000 C.O.I. in 7 patients. No maternal transmission, long NA treatment period, HBV DNA levels <3.0 log copies/mL, and reduced hepatitis B e antigen levels during the first 24 weeks of treatment were a significant factor of HBsAg levels <2000 C.O.I.. Conclusions: Hepatocarcinogenesis was observed in patients with high HBsAg levels, despite the negative conversion of HBV DNA as a result of long-term NA therapy. Therefore, to suppress hepatocarcinogenesis, it is important to control not only HBV DNA levels but also HBsAg levels.


Hepatic Medicine : Evidence and Research | 2013

Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study

Miwa Kawanaka; Ken Nishino; Jun Nakamura; Mitsuhiko Suehiro; Daisuke Goto; Noriyo Urata; Takahito Oka; Hirofumi Kawamoto; Hajime Nakamura; Junji Yodoi; Keisuke Hino; Gotaro Yamada

Background Nonalcoholic steatohepatitis (NASH) is a common liver disease that can progress to cirrhosis. Oxidative stress is one of the central mechanisms causing hepatocellular injury in the disease. In this study, antioxidant therapy using both vitamins C and E was conducted in patients with NASH. Methods Vitamin E 300 mg/day and vitamin C 300 mg/day were administered orally to 23 patients with NASH for 12 months. Body mass index was measured during therapy. Serum levels of alanine aminotransferase, thioredoxin (an oxidative stress marker), and high-sensitivity C-reactive protein were measured before treatment and after 12 months in all patients. Ten of the 23 patients underwent liver biopsy before and after treatment. Results Body mass index remained unchanged during treatment with vitamins C and E. Serum alanine aminotransferase, thioredoxin, and high-sensitivity C-reactive protein levels were decreased significantly at 12 months compared with pretreatment. Liver biopsies showed improved necroinflammatory activity in eight cases and improved fibrosis staging in 4. Conclusion Serum alanine aminotransferase, thioredoxin, and high-sensitivity C-reactive protein levels, and liver histology were clearly improved with vitamin C and E therapy. These findings suggest that combination therapy using these vitamins may be useful in patients with NASH to minimize damage from oxidative stress and slow the processes leading to cirrhosis.


Annals of Hepatology | 2015

Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease.

Miwa Kawanaka; Ken Nishino; Jun Nakamura; Noriyo Urata; Takahito Oka; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Gotaro Yamada

BACKGROUND Diagnosis of non-alcoholic fatty liver disease (NAFLD) is limited by the need for liver biopsies. Serum cytokeratin 18 (CK-18) levels have been investigated as potential biomarkers for the presence of NAFLD and non-alcoholic steatohepatitis (NASH). Herein, we assessed the correlation between CK-18 levels and NAFLD progression. MATERIAL AND METHODS Serum CK-18 levels were estimated using the M30 antibody enzyme-linked immunosorbent assay in 147 patients diagnosed with NAFLD. In 72 patients, disease progression was evaluated by repeated liver biopsy, which was conducted after 4.3 ± 2.6 years. The relationship between the CK-18 levels and liver histological findings was assessed. RESULTS The CK-18 levels were useful for identifying NAFLD patients with NAFLD activity scores (NAS) ≥ 5 (NAS ≥ 5 vs. ≤ 4: 675.1 U/L vs. 348.7 U/L; p < 0.0001). A cut-off value of 375 U/L was calculated using the receiver operating characteristic curve approach, with a specificity and sensitivity of 81.5 and 65%, respectively, for the diagnosis of NASH. Among the 72 patients who underwent repeated liver biopsy, 11 patients with a progressed NAS also had significantly increased serum CK-18 levels (p < 0.01); in 30 patients with an improved NAS, there was a significant improvement in the mean CK-18 levels (p < 0.0001). The 31 patients with static NAS had static CK-18 levels. CONCLUSIONS In conclusion, serum CK-18 levels can predict NAS ≥ 5 in NAFLD patients. In NAFLD patients, serum CK-18 levels reflect NAS values and correlate with histological changes, and they appear to be useful indicators of progression and improvement.


Hepatic Medicine : Evidence and Research | 2015

Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease.

Miwa Kawanaka; Ken Nishino; Takahito Oka; Noriyo Urata; Jun Nakamura; Mitsuhiko Suehiro; Hirofumi Kawamoto; Yasutaka Chiba; Gotaro Yamada

Objective Amino acid imbalance is often found in patients with cirrhosis, and this imbalance is associated with insulin resistance. However, the mechanism underlying the relationship between amino acid imbalance and insulin resistance remains unclear. We evaluated serum amino acid concentrations in patients with nonalcoholic fatty liver disease to determine if any of the levels of amino acids were associated with the biochemical markers and fibrosis stage of nonalcoholic steatohepatitis (NASH). Methods In 137 patients with nonalcoholic fatty liver disease who underwent liver biopsy, plasma levels of branched-chain amino acid (BCAA), tyrosine (Tyr), and the BCAA-to-Tyr ratio values were determined using mass spectroscopy. These values were then assessed for associations with fibrosis stage, anthropometric markers (age, sex, and body mass index), biochemical markers (alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transpeptidase, albumin, platelet count, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and glycosylated hemoglobin), and relevant disease-specific biomarkers (homeostasis model assessment of insulin resistance [HOMA-IR], serum iron, ferritin, leptin, adiponectin, high-sensitivity C-reactive protein, and hyaluronic acid). Results Serum albumin levels, plasma BCAA levels, and BCAA-to-Tyr ratio values were negatively associated with the fibrosis stage. In contrast, Tyr levels increased with increasing fibrotic staging. Tyr levels were also correlated with HOMA-IR results. Conclusion Plasma BCAA levels in patients with NASH decreased with increasing liver fibrosis, while Tyr levels increased with increasing fibrotic stage. These results suggest that amino acid imbalance and insulin resistance are intimately involved in a complex pathogenic mechanism for NASH.


Endocrinology, Diabetes & Metabolism Case Reports | 2018

Hypoinsulinemic hypoglycemia triggered by liver injury in elderly subjects with low body weight: case reports

Takatoshi Anno; Hideaki Kaneto; Ryo Shigemoto; Fumiko Kawasaki; Yasuhiro Kawai; Noriyo Urata; Hirofumi Kawamoto; Kohei Kaku; Niro Okimoto

Summary Hypoglycemia is induced by many causes, especially over-dose of insulin or oral hypoglycemic agents in diabetic subjects. In such a case, hyperinsulinemic hypoglycemia is usually observed. On the other hand, it is important to classify secondary hypoglycemia and hypoinsulinemic hypoglycemia. Liver injury-induced hypoglycemia is one of the causes of hypoinsulinemic hypoglycemia but rarely observed in clinical practice. Herein, we experienced similar 2 cases of non-diabetic hypoinsulinemic hypoglycemia. Both of them were elderly subjects with low body weight. Furthermore, it is likely that hypoinsulinemic hypoglycemia in both subjects was triggered by severe liver injury, at least in part, due to possible limited liver glycogen store. In elderly subjects with low body weight and/or malnutrition, metabolism in the liver is reduced and glycogen accumulation is decreased. Such alteration brings out acute and marked liver injury, which finally leads to the onset of severe hypoglycemia. It is known that not only liver injury but also multiple organ failure could be induced due to extreme emaciation in subjects. It is likely that in elderly subjects with low body weight and/or malnutrition, multiple organ failure including liver failure could be induced due to the similar reason. Therefore, we should be very careful of such subjects in order to avoid the development of multiple organ failure which leads to life-threatening situations. In conclusion, we should keep in mind the possibility of hypoinsulinemic hypoglycemia when we examine severe liver injury, especially in elderly or starving subjects with low body weight and limited liver glycogen stores. Learning points: It is important to classify secondary hypoglycemia and hypoinsulinemic hypoglycemia. Liver injury-induced hypoglycemia is one of the causes of hypoinsulinemic hypoglycemia but rarely observed in everyday clinical practice. Herein, we reported similar 2 cases of hypoinsulinemic hypoglycemia without diabetes presumably triggered by severe liver injury. In both cases, hypoglycemia was improved by glucose infusion, although their liver injury was not improved. We should keep in mind the possibility of hypoinsulinemic hypoglycemia when we examine severe liver injury, especially in elderly subjects with low body weight.


Radiology Case Reports | 2017

Ceftriaxone-associated pancreatitis captured on serial computed tomography scans

Nozomu Nakagawa; Nobuaki Ochi; Hiromichi Yamane; Yoshihiro Honda; Yasunari Nagasaki; Noriyo Urata; Hidekazu Nakanishi; Hirofumi Kawamoto; Nagio Takigawa

A 74-year-old man was treated with ceftriaxone for 5 days and subsequently experienced epigastric pain. Computed tomography (CT) was performed 7 and 3 days before epigastralgia. Although the first CT image revealed no radiographic signs in his biliary system, the second CT image revealed dense radiopaque material in the gallbladder lumen. The third CT image, taken at symptom onset, showed high density in the common bile duct and enlargement of the pancreatic head. This is a very rare case of pseudolithiasis involving the common bile duct, as captured on a series of CT images.


川崎医学会誌 | 2012

A prospective study showing poor prognosis in Japanese NASH patients with fibrosis stage F3-4

Miwa Kawanaka; Ken Nishino; Takahito Oka; Noriyo Urata; Jun Nakamura; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Gotaro Yamada


Gastrointestinal Endoscopy | 2017

Mo1178 Endoscopic Findings by Kyoto Classification Is Useful to Detect Helicobacter Pylori Infection in Young Patients

Mitsuhiko Suehiro; Ken Haruma; Tomoari Kamada; Jun Nakamura; Tomohiro Tanikawa; Noriyo Urata; Takahito Oka; Ken Nishino; Miwa Kawanaka; Noriaki Manabe; Akiko Shiotani; Hirofumi Kawamoto


Pancreatology | 2016

The pancreatic duct stent prevents post-ERCP pancreatitis effectively in the patients with naive papilla

Noriyo Urata; Tomohiro Tanikawa; Takahito Oka; Jun Nakamura; Ken Nishino; Mitsuhiko Suehiro; Miwa Kawanaka; Atsushi Urakami; Hirofumi Kawamoto


Gastrointestinal Endoscopy | 2016

Tu1733 Needle Knife Precutting Papillotomy Doesn't Seem to Be a Risk Factor of Post ERCP Pancreatitis at the Selective Biliary Deep Cannulation

Hirofumi Kawamoto; Tomohiro Tanikawa; Noriyo Urata; Takahito Oka; Jun Nakamura; Mitsuhiko Suehiro; Ken Nishino; Miwa Kawanaka; Ken Haruma

Collaboration


Dive into the Noriyo Urata's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jun Nakamura

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar

Ken Nishino

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takahito Oka

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ken Haruma

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge